Gilead Sciences (GILD) Set to Acquire Arcellx

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stem cell therapy stocks to buy. Gilead Sciences, Inc. (NASDAQ:GILD) ...
STAT

Gilead to buy Arcellx in nearly $8B deal

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Benzinga.com

Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug

Gilead Sciences on Monday agreed to acquire Arcellx for $115 per share in cash, along with a contingent value right of $5 per share, totaling an implied equity value of $7.8 billion. The BLA for ...
Morningstar

Gilead Sciences to Buy Arcellx in Deal Valuing Biotech at $7.8 Billion

Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing. Gilead on Monday said it will pay an initial ...